Prophylaxis Versus On-demand Therapy Through Economic Report

Inclusion Criteria: * age ≥ 12 years and ≤ 55 years * severe haemophilia A (FVIII \< 1%) * absence of inhibitors (Bethesda titre \< 0.6 BU/ml) * Previous Treated Patients (prior exposure days \> 200) * Kogenate Bayer administered 20-30 IU/kg -3 times a week, for the prophylaxis group * ≥ 6 joint bleeds requiring treatment with FVIII concentrates in the previous 6 months before enrollment, for on-demand group * written informed consent Exclusion Criteria: * concomitant severe and chronic diseases or congenital skeletal malformation * unreliability of patient or likelihood of follow-up failure * presence of inhibitors or history of inhibitors (in the previous 2 years) * currently on immune tolerance treatment * hepatic cirrhosis or liver disease in rapid progression * AIDS * platelet count \< 75,000/mm3 * presence of conditions that influence negatively patient´s compliance * participation in another study